Travere Therapeutics CFO Laura Clague to retire; Christopher Cline named successor effective Aug 31, 2022

Travere Therapeutics, Inc.

Laura Clague steps down as CFO on August 31, 2022 (or earlier if mutually agreed).
Christopher Cline, current SVP Investor Relations & Corporate Communications, appointed CFO on that date.
Clague remains employee through transition until March 31, 2023 at reduced base salary of $330,000 (70% of $471,000).
Clague eligible for 2022 bonus at 50% target and pro-rata 2023 bonus at 40% target; equity continues vesting.
Transition requires Clague to sign a general release on termination date.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Christopher Cline

Chief Financial Officer

TVTX · Travere Therapeutics, Inc.

Effective: 2022-08-31
Filed: April 20, 2022, 7:59 PM ET

Christopher Cline, the Company’s current Senior Vice President, Investor Relations and Corporate Communications has been named as Ms. Clague’s successor to be appointed as Chief Financial Officer, effective as of the Officer Resignation Date.

Departed

Laura Clague

Chief Financial Officer

TVTX · Travere Therapeutics, Inc.

Effective: 2022-08-31
Successor: Christopher Cline
Filed: April 20, 2022, 7:59 PM ET

On April 19, 2022, Travere Therapeutics, Inc. (the “Company”) and Laura Clague mutually agreed to the timeline and terms surrounding the planned retirement of Ms. Clague, who will step down from her position as the Company’s Chief Financial Officer effective as of August 31, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Cline was appointed as Chief Financial Officer at Travere Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

Christopher Cline, the Company’s current Senior Vice President, Investor Relations and Corporate Communications has been named as Ms. Clague’s successor to be appointed as Chief Financial Officer, effective as of the Officer Resignation Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Laura Clague retired as Chief Financial Officer at Travere Therapeutics, Inc..

Action: retired
Role: Chief Financial Officer

Exact text from the filing

On April 19, 2022, Travere Therapeutics, Inc. (the “Company”) and Laura Clague mutually agreed to the timeline and terms surrounding the planned retirement of Ms. Clague, who will step down from her position as the Company’s Chief Financial Officer effective as of August 31, 2022

View on SEC.gov

Travere Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001438533-22-000017

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.